NCT03850301View on ClinicalTrials.gov

Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

NARecruitingINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Multiple Sclerosis

Interventions

DRUG

XBD173

7 days treatment

DRUG

Etifoxine

7 days treatment

Trial Locations (1)

W12 0NN

RECRUITING

Imperial College Healthcare NHS Trust, London

All Listed Sponsors

lead

Imperial College London

OTHER